Odyssey Therapeutics, Inc.
Odyssey Therapeutics, Inc. is listed today as Odyssey Therapeutics, Inc.: market value, financials and filings are on its company page.
Funding rounds
3 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Jun 2025 | $214 M | No. 3 | $50 to $250 million | equity, options | SEC | |
| Oct 2023 | $117 M | No. 2 | $50 to $250 million | equity | SEC | |
| May 2022 | $168 M | No. 1 | $50 to $250 million | equity | SEC | |
| Aug 2021 | $92 M | Issued in a merger or acquisition | $50 to $250 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Odyssey Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Dec 2025).
SEC Form D · Dec 2025
The industry group it chose in its notices: Biotechnology.
SEC Form D · Dec 2025
That is all the official record says: Odyssey Therapeutics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services of Odyssey Therapeutics, Inc. are on record.
Investors#
5 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Anthony W. Opipari | Person | not stated | not stated | Held Series A, B, C and D preferred stock (Form 3, 2026) | SEC Form 3 |
| Dimension Capital II, L.P. | Fund or asset manager | not stated | not stated | Held Series D preferred stock, director (Form 3, 2026) | SEC Form 3 |
| Gary D. Glick | Person | not stated | not stated | Held Series C and D preferred stock, director (Form 3, 2026) | SEC Form 3 |
| SR One Capital Management, LLC | Fund or asset manager | not stated | not stated | Held Series A, A-2, B, C and D preferred stock, 10% owner (Form 3, 2026) | SEC Form 3 |
| Tpg Gp A, LLC | Fund or asset manager | not stated | not stated | Held Series D preferred stock, 10% owner (Form 3, 2026) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 55 investors.
Largest shareholders today
Institutions holding Odyssey Therapeutics, Inc. shares, as of Sep 30, 2026.
- FMR LLC$139 M12.98%
- SR One Capital Management, LP$84 M7.89%
- TPG GP A, LLC$82 M7.68%
- Lightspeed Management Company, L.L.C.$80 M7.51%
- Orbimed Advisors LLC$67 M6.24%
- Sanofi$44 M4.14%
- MPM Bioimpact LLC$29 M2.68%
- Affinity Asset Advisors, LLC$28 M2.62%
- BlackRock, Inc.$25 M2.38%
- Deerfield Management Company, L.P.$23 M2.18%
- Woodline Partners LP$20 M1.90%
- Sands Capital Alternatives, LLC$19 M1.82%
- Hhlr Advisors, LTD.$18 M1.73%
- General Catalyst Group Management, LLC$18 M1.69%
- Vanguard Capital Management LLC$16 M1.53%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Gary D. Glick | Executive officer | Dec 2025 |
| Jason F. Haas | CFO | Dec 2025 |
| Gary D Glick | Executive officer | Oct 2022 |
| Carl D. Gordon | Director | Dec 2025 |
| Carolyn F. Ng | Director | Dec 2025 |
| Gary D. Glick | Director | Dec 2025 |
| Jeffrey D. Leiden | Director | Dec 2025 |
| Jill D. Carroll | Director | Dec 2025 |
| Ksenija F. Pavletic | Director | Dec 2025 |
| Nan D. Li | Director | Dec 2025 |
| Nia F. Tatsis | Director | Dec 2025 |
| Paulina D. Hill | Director | Dec 2025 |
| Shelley F. Chu | Director | Dec 2025 |
| Timothy D. Walbert | Director | Dec 2025 |
| Valerie D. Odegard | Director | Dec 2025 |
| lan F. Smith | Director | Dec 2025 |
| Charles M. Baum | Director | Aug 2024 |
| Ian M. Smith | Director | Aug 2024 |
| Jeffrey M. Leiden | Director | Aug 2024 |
| Lorence M. Kim | Director | Aug 2024 |
| Timothy M. Walbert | Director | Aug 2024 |
| Jeffrey Charles Leiden | Director | Dec 2023 |
| Lorence Charles Kim | Director | Dec 2023 |
| M. Charles Baum | Director | Dec 2023 |
| Carl D Gordon | Director | Oct 2022 |
| Charles D Baum | Director | Oct 2022 |
| Gary D Glick | Director | Oct 2022 |
| Jeffrey D Leiden | Director | Oct 2022 |
| Jill D Carroll | Director | Oct 2022 |
| Valerie D Odegard | Director | Oct 2022 |
| Chuck D Baum | Director | Oct 2021 |
Went public since 2026. Its SEC number is that of a company listed on a stock exchange.